Zoetis (ZTS): Growth Reset After Companion Animal Slowdown
Zoetis remains a high-quality animal health leader, but slower companion animal demand, heavier discounting, and a reduced 2026 outlook keep the stock in Hold territory. Livestock and diagnostics are offsetting some weakness, yet the earnings reset is still underway.
Zoetis (ZTS) is not a bad investment right now, but it is only a Hold after earning an overall grade of B-. The stock’s fair value is $88.38, and the current setup looks more like a patient entry point than an immediate buy as companion animal demand softens and 2026 EPS guidance resets lower.
Thesis
Zoetis (ZTS) combines the strongest scale position in animal health with excellent margins, recurring product demand, and a broad innovation pipeline. The investment case is temporarily restrained by a sharp slowdown in companion animal demand, heavier discounting, generic competition, and elevated leverage. At $83.19, ZTS trades at 13.6x trailing earnings, 13.9x forward earnings, and carries a 10.3% free cash flow yield. That is a reasonable entry point for a moderate-risk investor, but the reduced 2026 outlook makes a Hold more appropriate than an aggressive Buy.
The central tension is visible in the latest quarter. Q2 2026 revenue was $2.47B, flat year over year, while adjusted EPS rose 5% to $1.87. Livestock revenue increased 11% and diagnostics revenue increased 12%, but global companion animal revenue fell 6%. Management reduced 2026 adjusted EPS guidance to $6.15 to $6.25 from $6.85 to $7.00. ZTS still owns valuable franchises, but the earnings engine needs time to reset.
The medium-term case rests on four facts: 2025 revenue reached $9.47B, net income reached $2.67B, operating margin reached 38.0%, and the company says its pipeline contains 12 potential blockbusters. The counterweight is a $9.1B debt balance against $2.3B of cash at year-end 2025, alongside a debt-to-equity ratio of 2.7. This is a high-quality business with a temporarily impaired growth profile, not a balance-sheet bargain.
Company Overview
Zoetis is a global animal health company that discovers, develops, manufactures, and sells medicines, vaccines, diagnostics, genetic tests, and precision animal health products. Its portfolio covers dogs, cats, horses, cattle, swine, poultry, fish, and sheep. The company sells products in more than 100 countries and directly markets them in approximately 45 countries.
The business is organized into U.S. and International operating segments. The U.S. generated $5.10B, or 54% of 2025 revenue, while International generated $4.25B, or 45%. Companion animal products represented approximately 70% of 2025 revenue, with livestock contributing approximately 29%. The remaining revenue came from contract manufacturing and human health products.
▌Common Questions
Frequently asked questions
+Is ZTS stock a buy right now?
Zoetis is a Hold right now, not a Buy. The business is still high quality, but slower companion animal demand, heavier discounting, and a lower 2026 EPS outlook mean the stock needs more proof of reacceleration before it deserves a more aggressive rating.
+What is ZTS's fair value?
Zoetis's fair value is $88.38. That view reflects the stock’s 13.9x forward earnings multiple, the company’s 2026 EPS guide of $6.15-$6.25, and the offsetting strength in livestock, diagnostics, and margin durability that keeps the valuation above a pure slowdown discount.
+Why did Zoetis get a Hold rating?
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
Zoetis had approximately 14,500 employees and a nearly 75-year operating history in animal health. Its scale creates commercial reach, regulatory experience, manufacturing depth, and customer relationships that smaller specialists must work harder to replicate. That scale does not prevent a downturn, as Q2 2026 showed, but it gives ZTS more levers to defend share.
Business Segment Deep Dive
The U.S. remains the earnings center but was the weaker geographic segment in Q2 2026. U.S. revenue fell 7% to $1.30B, with U.S. companion animal revenue down 11% and U.S. livestock revenue up 23% to $222M. International revenue rose 6% organically to $1.17B, supported by livestock, diagnostics, parasiticides, and emerging-market growth.
Global companion animal revenue was $1.7B in Q2, down 6%. Key Dermatology revenue fell 16% to $395M, while canine osteoarthritis pain monoclonal antibodies fell 8% to $105M. Feline osteoarthritis pain monoclonal antibodies grew 12% to $42M. The split shows that the portfolio is not moving as one block: mature U.S. categories are under pressure, while newer international and feline offerings are gaining traction.
Livestock provided the clearest offset. Global livestock revenue increased 11% in Q2, including 23% growth in the U.S. and 6% growth internationally. Cattle demand benefited from New World screwworm treatment needs, while poultry benefited from vaccines, hatchery programs, new contracts, and tender wins. Management expects U.S. livestock growth to moderate to the mid-single-digit range in the second half, so the Q2 surge should not be treated as a permanent new baseline.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Simparica and Simparica Trio are the largest product franchise, contributing approximately 16% of 2025 revenue. In Q2 2026, the franchise generated $442M and was flat globally. Simparica Trio generated $350M, down 1%, while Simparica generated $91M, up 4%. International Simparica revenue grew 19%, including 34% growth for Simparica Trio, but U.S. Simparica revenue fell 6%.
Simparica Trio held approximately 21% of U.S. in-clinic oral parasiticide share, nearly twice the share of its nearest competitor. Its U.S. puppy share was approximately 28%, above overall share, providing a specific foothold for future adoption. The current problem is not a lack of franchise relevance. It is that lower clinic traffic, promotional activity, and affordability pressure are reducing the value captured per patient.
Apoquel and Apoquel Chewable contributed approximately 12% of 2025 revenue. The dermatology franchise remains the U.S. market leader with approximately 86% of in-clinic share, despite a 5-point sequential decline and a 10-point year-over-year decline in Q2. Cytopoint, Apoquel, and the expected U.S. approval of long-acting Cytopoint give ZTS a broad dermatology platform, but the franchise is currently absorbing the greatest competitive damage.
Diagnostics generated $118M in Q2, up 12%, driven by Vetscan Imagyst and OptiCell. The company also completed the VitalRADS acquisition, adding veterinary teleradiology capabilities. Diagnostics is smaller than parasiticides or dermatology, but its recurring instruments, consumables, laboratory services, and workflow integration make it strategically important.
Innovation & Competitive Advantage
Zoetis has built its moat through product breadth, regulatory expertise, veterinary relationships, and lifecycle innovation. The 2025 annual report lists approximately 300 product lines across seven major categories. The company has also built a patent estate with more than 5,500 granted patents and 1,600 pending applications.
Lifecycle innovation is a practical advantage in animal health. Simparica expanded from flea and tick control into a three-in-one product covering fleas, ticks, heartworm, and gastrointestinal parasites. Apoquel gained chewable formulations and additional geographic approvals. Librela, Lenivia, Solensia, and Portela extend monoclonal antibody treatment across canine and feline osteoarthritis.
The current pipeline is valuable because it can reduce dependence on mature franchises. Vetscan OmniMax is a potential diagnostics blockbuster, while long-acting Cytopoint, Lenivia, and Portela address convenience and treatment adherence. The risk is execution: the Q2 results show that even a category leader can lose share quickly when competitors combine lower prices with rebates and portfolio bundling.
Operations & Supply Chain
Zoetis operates 21 manufacturing facilities and maintains a global distribution network. Its products range from conventional medicines to vaccines, biologics, diagnostics instruments, reagents, and laboratory services. That breadth supports customer retention but also raises manufacturing and quality-control demands.
Management created a combined CFO and COO role in August 2026, giving Jay Saccaro oversight of finance, global manufacturing, and supply. The stated objective is faster decision-making and stronger connectivity across the supply chain. The change is material because management also cited improved product supply as one reason for the strong Q2 livestock result.
Zoetis is expanding U.S. manufacturing capacity with a companion animal biologics site in Atlanta expected to be operational by 2029. That project is a medium-term capacity investment rather than an immediate earnings driver. In the near term, the company is emphasizing cost discipline, targeted commercial spending, and protection of high-return innovation.
Market Analysis
Zoetis addresses a market divided between companion animal care and livestock production. Companion animal products accounted for approximately 70% of 2025 revenue, reflecting demand for dermatology, parasiticides, vaccines, pain treatment, and diagnostics. Livestock products accounted for approximately 29%, supported by animal protein production, disease prevention, and productivity needs.
The product mix is broad. 2025 revenue was composed of approximately 25% parasiticides, 21% vaccines, 19% dermatology, 11% anti-infectives, 9% pain and sedation, 7% other pharmaceuticals, and 5% diagnostics. That mix creates multiple demand pools, but the 2026 results show that the largest categories can still move together when clinic traffic and affordability deteriorate.
The strongest current market evidence favors diagnostics, livestock, feline care, and international parasiticide adoption. The weakest evidence concerns U.S. premium companion animal therapies, where clinic visits declined, pet owners became more selective, and competitors increased promotional incentives. ZTS therefore has a large addressable market, but near-term growth depends more on execution and category stabilization than on market size alone.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Zoetis sells to veterinarians, pet owners, livestock producers, distributors, and diagnostic laboratories. Veterinarians influence prescribing, product education, and treatment standards. Pet owners influence affordability and adherence. Livestock producers and veterinarians weigh disease prevention against animal productivity, food safety, and operating economics.
Q2 2026 showed how these customer groups behave under pressure. U.S. companion animal demand weakened as veterinary visits declined and pet owners became more price sensitive. Urgent and emergency care held up better than premium preventative and chronic care. ZTS responded with targeted pricing, promotions, and gross-to-net investments designed to protect volume, especially in Apoquel and Simparica.
Customer concentration is balanced geographically. The U.S. supplied 54% of 2025 revenue and International supplied 45%. Emerging markets supported Q2 growth across companion animal, livestock, and diagnostics, while developed European markets faced more intense competition. This geographic mix gives ZTS growth avenues beyond the U.S., although currency movements and local regulatory systems add complexity.
Competitive Landscape
The principal competitors include Elanco Animal Health (ELAN), Merck Animal Health, and Boehringer Ingelheim Animal Health. ZTS also competes with generic manufacturers, regional specialists, start-ups, and animal health divisions of larger pharmaceutical companies. Competition occurs across product development, quality, price, service, distribution, and promotion.
ZTS retains meaningful category leadership. Its U.S. dermatology franchise held approximately 86% of in-clinic share in Q2, and Simparica Trio held approximately 21% of U.S. oral parasiticide share, nearly twice the share of its nearest competitor. These positions show that the company has a commercial moat, but the 10-point annual dermatology share decline also shows that the moat is not automatic.
Generic erosion is a measurable risk. Cerenia and Convenia faced generic competition in the U.S. during Q2, and the 2025 annual report identifies significant erosion in products such as Draxxin and the Excede and Naxcel lines. ZTS can defend volume through pricing, but that strategy reduces price realization and can pressure margins if used too broadly.
Macro & Geopolitical Landscape
The most important macro factor for ZTS is household affordability in companion animal care. Management linked Q2 weakness to lower clinic visits, pet owner price sensitivity, and promotional competition. That pressure hit premium therapies such as Apoquel, Cytopoint, and canine osteoarthritis products more severely than urgent care.
Livestock is exposed to different forces. Q2 cattle demand benefited from New World screwworm treatment needs, favorable producer economics, and improved product supply. International livestock growth also reflected global protein demand, while Brazil experienced macroeconomic pressure and lower medicalization after mandatory foot-and-mouth disease vaccinations ended.
The 2025 10-K identifies currency fluctuations, capital controls, exchange controls, expropriation, and restrictive government actions as international risks. ZTS also operates in heavily regulated markets where product approvals, manufacturing compliance, labeling, and animal disease policy affect revenue timing. Its global reach is an advantage, but it creates a wider surface area for regulatory and geopolitical disruption.
Balance Sheet Health
▌Premium Members Only
A $9.1B debt load against $2.3B of cash and a 2.7 debt-to-equity ratio leave Zoetis with solid scale but limited balance-sheet flexibility.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
At $83.19, Zoetis trades at 13.6x trailing earnings, 13.9x forward earnings, and a 10.3% free cash flow yield, which is reasonable but not a clear bargain.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Zoetis remains the leading animal health platform, supported by $9.47B of 2025 revenue, 38.0% operating margin, global distribution, and a portfolio spanning medicines, vaccines, diagnostics, and biologics. The business has repeatedly shown that it can create new categories, expand existing products, and use its commercial network to defend market share.
The investment case is more balanced than the company’s long-term reputation suggests. Q2 2026 exposed meaningful weaknesses in U.S. companion animal demand, while the debt balance increased and 2026 guidance fell. At the same time, livestock grew 11%, diagnostics grew 12%, international Simparica grew 19%, and analysts still project EPS growth through 2030.
For a medium-term investor, the appropriate stance is patience rather than urgency. The stock has credible recovery assets, but the market needs evidence that price concessions are protecting volume without permanently damaging margins. Until that evidence arrives, ZTS earns a Hold with an $88.38 fair value estimate and a preference for buying at $79 or below.
Zoetis earned an overall grade of B- and a Hold because the core franchise is strong, but growth has clearly slowed. Q2 revenue was flat at $2.47B, companion animal revenue fell 6%, and management cut 2026 EPS guidance, which outweighs the company’s excellent margins and scale for now.
+What are the biggest risks for ZTS stock?
The biggest risks are continued weakness in companion animal demand, heavier discounting, and leverage. Zoetis ended 2025 with $9.1B of debt versus $2.3B of cash, so the company has less room to absorb a prolonged earnings reset if the slowdown lasts.
+What could drive ZTS higher from here?
A rebound in companion animal demand, better monetization of Simparica Trio and Apoquel, and continued strength in livestock and diagnostics could lift the stock. Zoetis also has a pipeline with 12 potential blockbusters, so pipeline execution could help restore growth momentum.
▌For Active Investors
Want Reports Like This on Any Stock?
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.